American Society of Clinical Oncology steunt WIN Symposium 2016: innovatieve aanpak voor verbeterde resultaten bij kankerpatiënten
VILLEJUIF, France–(BUSINESS WIRE)– Het WIN Consortium (WIN) is verheugd aan te kondigen dat zijn symposium ‘Innovative approaches to improve cancer patient outcomes’ steun krijgt van de American Society of Clinical Oncology (ASCO®), wegens zijn buitengewone wetenschappelijke programma. “Het is het achtste opeenvolgende jaar waarin ASCO haar steun uitspreekt voor dit unieke wetenschapsforum, dat is uitgegroeid tot een belangrijk evenement voor precisiemedicijnen tegen kanker”, zei John Mendelsohn, directeur van het Anderson Institute for Personalized Cancer Therapy and Chairman van WIN.
Het symposium van 2016 is van grote waarde, omdat bijzonder uitdagende en controversiële thema’s aan bod komen. Precisiemedicijnen zijn, zoals Amerikaans president Barack Obama eerder al aankondigde, een cruciaal doel van de oncologische gemeenschap.
The American Society of Clinical Oncology® Endorses the WIN 2016 Symposium: Innovative Approaches to Improve Cancer Patient Outcomes
VILLEJUIF, France–(BUSINESS WIRE)– The WIN Consortium (WIN) is proud to announce that its symposium dedicated to “Innovative approaches to improve cancer patient outcomes” has been endorsed by the American Society of Clinical Oncology (ASCO®) for its exceptional scientific program. “It is the 8 th consecutive year that ASCO® has endorsed this unique scientific forum, that has become a major event in Precision Cancer Medicine”, said John Mendelsohn, Director for MD Anderson Institute for Personalized Cancer Therapy and Chairman of WIN.
WIN 2016’s symposium will be of exceptional value, as it will address very challenging and controversial themes. Precision medicine, as announced by the US President Barack Obama, has become a key objective shared by the oncology community. A special forum will be dedicated to discuss how to expedite precision cancer medicine with the outstanding participation of Bruce E. Johnson (ASCO® 2017 president elect), Richard L. Schilsky (ASCO®’s Chief Medical Officer and Chairman of WIN Scientific Advisory Board), Razelle Kurzrock (UCSD), William Sellers (Novartis), John Mendelsohn and many others.
The WIN symposium has increasingly become the forum where academia and industry share in a very candid way the latest innovations in cancer personalized medicine. But since there is no innovation without patients, this year, WIN2016 will present the opportunity for patient advocates to voice their opinions, in particular, Francesco de Lorenzo, the President of the European Cancer Patient Coalition (ECPC).
The greatest experts in the field of personalized and systems biology medicine in oncology will contribute to the program under the chairmanship of Dr. Josep Tabernero (Vall d’Hebron, Spain): Alberto Bardelli, Andrea Califano, Stephen Friend, Leroy Hood, Gordon B. Mills, and many others from academia, industry and cancer research organizations. They will present the latest innovations aiming at improving the survival and quality of life of cancer patients in the following sessions:
- New tools for early diagnosis, selecting therapies and monitoring
- Innovative clinical trials to substantially improve outcome
- Relevant models and critical preclinical data before moving to the clinic
- Translation of big data into clinical opportunities
The WIN 2016 symposium is the only event of its kind that enables all stakeholders of cancer care, from academia to industry, to present their latest advances.
For more information, take a look at www.winsymposium.org
This program is endorsed by ASCO®. ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. used with permission. This is not an ASCO® sponsored event.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420005105/en/
Contacts
WIN Consortium
Vladimir Lazar
Chief Operating Officer
Vladimir.lazar@winconsortium.org